Kuvatris Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Kuvatris Therapeutics Inc in the third quarter 2024?
Due to the lack of equity, it was not possible to calculate Kuvatris Therapeutics Inc 's return on equity (ROE) in its third quarter 2024

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter
Y / Y Equity Change	-	-	-53.02 %	3011.28 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-14	-18	-18	-18	-12
Return On Equity (TTM)	-6479.84 %	-3167.06 %	-1151.68 %	-956.79 %	-1133.4 %
PXMD's Total Ranking	# 3879	# 3841	# 3215	# 2105	# 3934
Equity (TTM) in Millions	-2	-2	1	3	-1
Seq. Equity Change	-	-	-64.85 %	-	-
Seq. Net Income Change	-	-	-	-	-

Back to PXMD Management Effectiveness >> PXMD's 5 Years Annual ROE >> Compare PXMD ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 384
Sector	# 796
Overall	# 3879

Return On Equity Statistics
High	Average	Low
-956.79 %	-2319.9 %	-6479.84 %
(Dec 31 2023)		(Sep 30 2024)

News about Kuvatris Therapeutics Inc Return on Equity ROE

PaxMedica Revolutionizes Autism Spectrum Disorder Treatments with Groundbreaking Innovations

PaxMedica Unveils Innovations in Autism Spectrum Disorder Treatments in Latest Company Presentation
TARRYTOWN, New York, March 13, 2024 - PaxMedica, Inc. (NASDAQ: PXMD), a leading biopharmaceutical company specializing in neurological disorder treatments, announced today the release of its latest company presentation. This comprehensive overview highlights PaxMedica s strategic direction, recent advancements in Autism Spectrum Disorder (ASD) therapeutics, and its unwavering commitment to addressing the unmet needs of the ASD community.
PaxMedica has long been at the forefront of developing innovative treatments for neurological disorders, with a particular focus on ASD. This latest company presentation showcases their dedication to advancing research in this field and introduces groundbreaking advancements that offer hope to individuals and families affected by ASD.

PXMD Annual Return On Equity	(Dec 31 2023) 2023	(Dec 31 2022) 2022
Total Equity in Millions	3	0	0	0	0
Y / Y Equity Change	3011.28 %	-	-	-	-
Net Income in Millions	-18	-15	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-540.31 %	-13604.57 %	-	-	-

Back to PXMD Management Effectiveness >> PXMD's 5 Years Annual ROE >> Compare PXMD ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PXMD's' Return on Equity at Yahoo Finance
PXMD's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PXMD's Competitors
Subscribers only: Roe for Kuvatris Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for PXMD's Customers

Companies with similar Return On Equity at Sep 30 2024, within Healthcare Sector

ROE

Date modified: 2026-06-22T14:32:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.